Condition
Sarcoma, Alveolar Soft Part
Total Trials
4
Recruiting
0
Active
0
Completed
4
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 25/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
75%
3 of 4 completed with results
Key Signals
3 with results100% success
Data Visualizations
Phase Distribution
4Total
P 1 (1)
P 2 (3)
Trial Status
Completed4
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT01391962Phase 2CompletedPrimary
Sunitinib or Cediranib for Alveolar Soft Part Sarcoma
NCT00942877Phase 2CompletedPrimary
Phase II Study of Cediranib (AZD2171) in Patients With Alveolar Soft Part Sarcoma
NCT00258687Phase 1Completed
Vaccine Trial for Clear Cell Sarcoma, Pediatric Renal Cell Carcinoma, Alveolar Soft Part Sarcoma and Children With Stage IV Melanoma
NCT00464620Phase 2Completed
Trial of Dasatinib in Advanced Sarcomas
Showing all 4 trials